Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

$15 million federal funds for new cancer research program

As a result of C3: Colorectal Cancer Coalition's advocacy efforts, $15 million for a new peer reviewed cancer research program is included in the final Fiscal Year 2010 Defense Appropriations Bill.

17 Dec 2009

EDP Biotech develops a simple blood test for detecting early-stage colon cancer

Medical researchers with EDP Biotech Corporation (EDP) have captured national attention with their revolutionary new technology for a simple blood test to detect early-stage colon cancer.

16 Dec 2009

Increased physical activity decreases risk of colorectal cancer

Increased physical activity appears to be associated with a lower risk of cancer-specific and overall death in men with a history of colorectal cancer that has not spread to other parts of the body, according to a report in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

Regular exercise can reduce mortality rate for patients with colorectal cancer

Men who have been treated for colorectal cancer can reduce their risk of dying from the disease by engaging in regular exercise, according to a new study by researchers at Dana-Farber Cancer Institute. The findings are published in the December 14 issue of the Archives of Internal Medicine.

15 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Cequent Pharmaceuticals' IND application for CEQ508 approved for clinical trial

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday.

10 Dec 2009

Drop in U.S. colorectal cancer deaths

The American Society for Gastrointestinal Endoscopy (ASGE) lauds the recent news of the decline in U.S. colorectal cancer death and incidence rates. The report, released this week, shows that from 1975 to 2000, incidence rates dropped 22 percent and death rates dropped 26 percent.

10 Dec 2009

Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement

Pro-Pharmaceuticals, Inc., today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $4.4 million.

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

German researchers study target-oriented methods for children with brain tumor

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer tremendously from the stressful treatment which can be harmful to the developing brain.

10 Dec 2009

Research article addresses the relationship between PEG and GER

Gastroesophageal reflux (GER) is a common problem in mechanically ventilated patients and contributes to the development of esophageal mucosal injury and even erosive esophagitis. The relationship between percutaneous endoscopic gastrostomy (PEG) and subsequent development of GER is complex and not well understood.

9 Dec 2009

Research article on Peliosis hepatis

Peliosis hepatis (PH) is a rare pathological entity. PH varies from minimal asymptomatic lesions to larger massive lesions that may present with cholestasis, liver failure, portal hypertension, avascular mass lesion, or even spontaneous rupture.

9 Dec 2009

People living in deprived neighborhoods more likely to die from cancer and heart disease

Regardless of an individual's dietary and lifestyle risk factors, living in a poorer or more socioeconomically deprived neighborhood may increase a person's risk for death, according to data presented at the American Association for Cancer Research Conference on Frontiers in Cancer Prevention Research, held Dec. 6-9, 2009.

9 Dec 2009

Comparative study on erosive and nonerosive diseases

Gastroesophageal reflux disease (GERD) is defined as the pathological retrograde movement of gastric contents into the esophagus. Various esophageal motility disturbances which may be important in reflux are observed in patients with GERD.

9 Dec 2009

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass.

9 Dec 2009

Colon Cancer Alliance's statement regarding a new report on drop in colorectal cancer

A recent study by the Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) highlighting that the death rate from colorectal cancer over the last decade dropped nearly 20 percent and that by 2020 could be cut in half is welcomed news.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Consumer reports details the screening tests that may be unneccesary

Consumer Reports/The Washington Post: "Many Americans -- and their doctors -- seem to think that better health means more health care, including as many screening tests as possible. But many researchers are questioning that notion, saying that some common screening tests are unproven and can not only waste your time and money but also cause more harm than good."

8 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009